SCHEMBL1886922

SCHEMBL1886922

CC1(C)CN(S(=O)(=O)c2cc(F)cc(F)c2)Cc2c(NC(=O)c3cccnc3NC(=O)C3CCCO3)n[nH]c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK4 O96013 2/20 0.40
NTRK1 P04629 6/20 0.39
IGF1R P08069 3/20 0.39
CCNA2 P20248 3/20 0.37
CDK2 P24941 3/20 0.37
CCNA1 P78396 3/20 0.37
PRKCB P05771 1/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNE1 P24864 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
NTRK3 Q16288 2/20 0.36
NTRK2 Q16620 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886919 1.00 PAK4 (0.40) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1888704 1.00 PAK4 (0.40) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1892434 0.91 LMNA (0.45) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1883266 0.91 LMNA (0.45) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1889568 0.90 NTRK1 (0.39) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1888679 0.90 NTRK1 (0.39) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1886602 0.90 IGF1R (0.41) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1885528 0.88 IGF1R (0.39) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1891450 0.88 IGF1R (0.39) PAK4NTRK1IGF1RCCNA2CDK2
SCHEMBL1885525 0.88 IGF1R (0.39) PAK4NTRK1IGF1RCCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 PAK4 44/4885NTRK1 1131/4885IGF1R 760/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 PAK4 44/4885NTRK1 1131/4885IGF1R 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.